<DOC>
	<DOCNO>NCT02836028</DOCNO>
	<brief_summary>The purpose phase 2 , multiple-cohort , randomize , open-label , international study talazoparib ( poly ( ADP-ribose ) polymerase ( PARP ) inhibitor ) compare efficacy safety talazoparib monotherapy talazoparib plus temozolomide woman relapse ovarian , fallopian tube , peritoneal cancer .</brief_summary>
	<brief_title>A Study Evaluating Talazoparib Relapsed Ovarian , Fallopian Tube , Peritoneal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Talazoparib</mesh_term>
	<criteria>Women ≥ 18 year age willing able provide inform consent Relapsed , histologically confirm ovarian , fallopian tube , peritoneal cancer . Histologic subtypes include serous , endometrioid , clearcell , mixed , undifferentiated histology , carcinosarcoma . Sufficient archival tumor tissue available consent fresh tissue biopsy biomarker analysis . Consent blood sample collection biomarker analysis require . Disease progression per RECIST 1.1 last treatment . Have metastatic disease least 1 target tumor lesion measurable per RECIST 1.1 screen scan . Lesions use biopsy designate measurable lesion RECIST 1.1 assessment . Additional criterion cohort 1 include follow : Have deleterious germline somatic BRCA1 BRCA2 mutation , high diagnostic HRD test score ( myChoice score ≥ 42 ) , represent loss DNA repair function base test perform sponsorapproved laboratory Received least 1 3 platinumbased chemotherapy regimen ( prior bevacizumab allow ) last dose ≥ 28 day randomization No prior PARP inhibitor treatment ( COHORT 1 ONLY ) Additional criterion cohorts 2 3 include following : Received least 2 platinumbased chemotherapy regimen ( include firstline chemotherapy ; prior bevacizumab allow ) last dose ≥ 28 day randomization Received prior PARP inhibitor treatment single agent combination therapy regimen last dose ≥ 28 day randomization , follow : For cohort 2 : Received PARP inhibitor treatment ≥ 6 month response CR , PR , stable disease ≥ 6 month For cohort 3 : Received PARP inhibitor treatment &lt; 6 month response ( disease progression stable disease ) Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . Estimated life expectancy ≥ 3 month . Able swallow drug , know intolerance study drug excipients , able comply study requirement . Have recover ( recovery define National Cancer Institute Common Terminology Criteria Adverse Events [ CTCAE ] grade ≤ 1 ) acute toxicity previous therapy , except treatmentrelated alopecia laboratory abnormality otherwise meet eligibility requirement . Use investigational agent within 14 day randomization . Had &gt; 2 paracentesis procedure within 28 day randomization . Major surgery within 14 day randomization . Requirement intravenous alimentation ( time randomization ) . Diagnosis MDS .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>